Literature DB >> 16896641

Prediction of non-responsiveness to standard high-dose gamma-globulin therapy in patients with acute Kawasaki disease before starting initial treatment.

Tetsuya Sano1, Shunji Kurotobi, Kouji Matsuzaki, Takehisa Yamamoto, Ichiro Maki, Kazunori Miki, Shigetoyo Kogaki, Junichi Hara.   

Abstract

Clinical, laboratory, and echocardiographic data were retrospectively analyzed in 112 patients with acute Kawasaki disease who received high-dose (2 g/kg) intravenous gamma-globulin (IVIG) treatment within 2 days and were compared for those who were responsive and non-responsive to initial IVIG treatment. Coronary arteries adjusted for body surface area (BSA) were evaluated quantitatively by comparison with the mean dimensions for 85 normal control subjects. The incidence of coronary abnormalities was higher in IVIG-non-responsive patients as compared to IVIG-responsive patients (71% versus 5%, p<0.0001). Univariate analysis of pre-IVIG data showed that the neutrophil count and serum levels of C-reactive protein (CRP), total bilirubin (TB), aspartate aminotransferase (AST), alanine aminotransferase, and lactate dehydrogenase (LDH) were significantly higher in IVIG-non-responsive versus responsive patients. Multivariate analysis selected CRP (p=0.009), TB (p<0.001), and AST (p=0.002) as independent predictors of non-responsiveness to initial IVIG treatment. By defining predictive values, patients with at least two of three predictors (CRP>or=7.0 mg, TB>or=0.9 mg, or AST>or=200 IU/L) are considered to be non-responsive to IVIG for acute Kawasaki disease. Alternatively, more intense initial therapy may be a promising therapeutic strategy for patients who are predicted to be IVIG-non-responsive.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16896641     DOI: 10.1007/s00431-006-0223-z

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  30 in total

1.  Prediction of non-responsiveness to intravenous high-dose gamma-globulin therapy in patients with Kawasaki disease at onset.

Authors:  M Fukunishi; M Kikkawa; K Hamana; T Onodera; K Matsuzaki; Y Matsumoto; J Hara
Journal:  J Pediatr       Date:  2000-08       Impact factor: 4.406

2.  Evaluation of the cytokine response in Kawasaki disease.

Authors:  B A Eberhard; U Andersson; R M Laxer; V Rose; E D Silverman
Journal:  Pediatr Infect Dis J       Date:  1995-03       Impact factor: 2.129

3.  Incidence survey of Kawasaki disease in 1997 and 1998 in Japan.

Authors:  H Yanagawa; Y Nakamura; M Yashiro; I Oki; S Hirata; T Zhang; T Kawasaki
Journal:  Pediatrics       Date:  2001-03       Impact factor: 7.124

4.  Plasminogen activator inhibitor-1 in patients with Kawasaki disease: diagnostic value for the prediction of coronary artery lesion and implication for a new mode of therapy.

Authors:  Hideaki Senzaki; Toshiki Kobayashi; Hironori Nagasaka; Hirofumi Nakano; Shunei Kyo; Yuji Yokote; Nozomu Sasakid
Journal:  Pediatr Res       Date:  2003-03-05       Impact factor: 3.756

5.  Treatment of intravenous immunoglobulin-resistant Kawasaki disease with methotrexate.

Authors:  S Y Ahn; D S Kim
Journal:  Scand J Rheumatol       Date:  2005 Mar-Apr       Impact factor: 3.641

6.  Coronary diameter in normal infants, children and patients with Kawasaki disease.

Authors:  Shunji Kurotobi; Toshisaburo Nagai; Nobuhiro Kawakami; Tetsuya Sano
Journal:  Pediatr Int       Date:  2002-02       Impact factor: 1.524

7.  [Acute febrile mucocutaneous syndrome with lymphoid involvement with specific desquamation of the fingers and toes in children].

Authors:  T Kawasaki
Journal:  Arerugi       Date:  1967-03

8.  Does Abciximab enhance regression of coronary aneurysms resulting from Kawasaki disease?

Authors:  Richard V Williams; Venus M Wilke; Lloyd Y Tani; L LuAnn Minich
Journal:  Pediatrics       Date:  2002-01       Impact factor: 7.124

9.  Novel and traditional cardiovascular risk factors in children after Kawasaki disease: implications for premature atherosclerosis.

Authors:  Yiu-fai Cheung; Tak-cheung Yung; Sidney C F Tam; Marco H K Ho; Adolphus K T Chau
Journal:  J Am Coll Cardiol       Date:  2004-01-07       Impact factor: 24.094

10.  High-dose intravenous gammaglobulin for Kawasaki disease.

Authors:  K Furusho; T Kamiya; H Nakano; N Kiyosawa; K Shinomiya; T Hayashidera; T Tamura; O Hirose; Y Manabe; T Yokoyama
Journal:  Lancet       Date:  1984-11-10       Impact factor: 79.321

View more
  118 in total

1.  Abnormal liver panel in acute kawasaki disease.

Authors:  Mohammed Eladawy; Samuel R Dominguez; Marsha S Anderson; Mary P Glodé
Journal:  Pediatr Infect Dis J       Date:  2011-02       Impact factor: 2.129

Review 2.  Use of corticosteroids during acute phase of Kawasaki disease.

Authors:  Jeong Jin Yu
Journal:  World J Clin Pediatr       Date:  2015-11-08

3.  Evolution of laboratory values in patients with Kawasaki disease.

Authors:  Adriana H Tremoulet; Sonia Jain; Divya Chandrasekar; Xiaoying Sun; Yuichiro Sato; Jane C Burns
Journal:  Pediatr Infect Dis J       Date:  2011-12       Impact factor: 2.129

4.  Identification of Differentially Expressed Genes in Kawasaki Disease Patients as Potential Biomarkers for IVIG Sensitivity by Bioinformatics Analysis.

Authors:  Lan He; Youyu Sheng; Chunyun Huang; Guoying Huang
Journal:  Pediatr Cardiol       Date:  2016-05-09       Impact factor: 1.655

5.  A Multicenter Study of Intravenous Immunoglobulin Non-response in Kawasaki Disease.

Authors:  Meng Wei; Meirong Huang; Shubao Chen; Guoying Huang; Min Huang; Dingzhong Qiu; Zhongzhen Guo; Jingjing Jiang; Xiaoxun Zhou; Qing Yu; Ying Guo; Lijun Fu; Wei Gao; Feng Li
Journal:  Pediatr Cardiol       Date:  2015-03-27       Impact factor: 1.655

6.  Tissue Doppler Imaging as a Predictor of Immunoglobulin Resistance in Kawasaki Disease.

Authors:  Daniel Phadke; Sonali S Patel; Samuel R Dominguez; Heather Heizer; Marsha S Anderson; Mary P Glode; Pei-Ni Jone
Journal:  Pediatr Cardiol       Date:  2015-05-21       Impact factor: 1.655

Review 7.  Immune Gamma Globulin Therapeutic Indications in Immune Deficiency and Autoimmunity.

Authors:  Luanna Yang; Eveline Y Wu; Teresa K Tarrant
Journal:  Curr Allergy Asthma Rep       Date:  2016-07       Impact factor: 4.806

8.  Prediction of intravenous immunoglobulin resistance in Kawasaki disease in an East China population.

Authors:  Yunjia Tang; Wenhua Yan; Ling Sun; Jie Huang; Weiguo Qian; Yueyue Ding; Haitao Lv
Journal:  Clin Rheumatol       Date:  2016-08-05       Impact factor: 2.980

9.  Non-coronary cardiac events, younger age, and IVIG unresponsiveness increase the risk for coronary aneurysms in Italian children with Kawasaki disease.

Authors:  Marianna Fabi; Laura Andreozzi; Ilaria Frabboni; Ada Dormi; Elena Corinaldesi; Francesca Lami; Cristina Cicero; Bertrand Tchana; Rosa Francavilla; Monica Sprocati; Barbara Bigucci; Claudia Balsamo; Paola Sogno Valin; Giorgia Di Fazzio; Lorenzo Iughetti; Enrico Valletta; Federico Marchetti; Andrea Donti; Marcello Lanari
Journal:  Clin Rheumatol       Date:  2020-09-16       Impact factor: 2.980

10.  Association of CCR2-CCR5 haplotypes and CCL3L1 copy number with Kawasaki Disease, coronary artery lesions, and IVIG responses in Japanese children.

Authors:  Manju Mamtani; Tomoyo Matsubara; Chisato Shimizu; Susumu Furukawa; Teiji Akagi; Yoshihiro Onouchi; Akira Hata; Akihiro Fujino; Weijing He; Sunil K Ahuja; Jane C Burns
Journal:  PLoS One       Date:  2010-07-07       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.